Monday May 29th 2017

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

Visit site: 

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Leave a Comment

More from category

New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep
New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep

A 5-year-old boy, who is profoundly disabled and has complex needs, has been given his first full night’s sleep [Read More]

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]